194 related articles for article (PubMed ID: 28741569)
1. Melanoma, Viagra, and PDE5 Inhibitors: Proliferation and Metastasis.
Houslay MD
Trends Cancer; 2016 Apr; 2(4):163-165. PubMed ID: 28741569
[TBL] [Abstract][Full Text] [Related]
2. [Erectile dysfunction, PDE5A inhibitors and melanoma].
Schmutz JL
Ann Dermatol Venereol; 2015 Dec; 142(12):800-1. PubMed ID: 26293983
[No Abstract] [Full Text] [Related]
3. [Current role of sildenafil in the management of erectile dysfunction].
Akhvlediani ND; Matyukhov IP
Urologiia; 2018 May; (2):142-146. PubMed ID: 29901310
[TBL] [Abstract][Full Text] [Related]
4. A Case Report: Consecutive Cranial Neuropathies Following the Use of Phosphodiesterase-5 Inhibitors.
van Landingham SW; Singman EL
Am Orthopt J; 2015; 65():109-14. PubMed ID: 26564936
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction: Pharmacology and Clinical Impact of the Sildenafil Citrate Orodispersible Tablet Formulation.
Scaglione F; Donde S; Hassan TA; Jannini EA
Clin Ther; 2017 Feb; 39(2):370-377. PubMed ID: 28139291
[TBL] [Abstract][Full Text] [Related]
6. Beyond Erectile Dysfunction: cGMP-Specific Phosphodiesterase 5 Inhibitors for Other Clinical Disorders.
Samidurai A; Xi L; Das A; Kukreja RC
Annu Rev Pharmacol Toxicol; 2023 Jan; 63():585-615. PubMed ID: 36206989
[TBL] [Abstract][Full Text] [Related]
7. [PDE-5 inhibitors: patients preferences].
Efremov EA; Kasatonova EV; Melnik YI; Nikushina AA
Urologiia; 2017 Jul; (3):120-126. PubMed ID: 28845950
[TBL] [Abstract][Full Text] [Related]
8. Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Loeb S; Folkvaljon Y; Lambe M; Robinson D; Garmo H; Ingvar C; Stattin P
JAMA; 2015 Jun 23-30; 313(24):2449-55. PubMed ID: 26103029
[TBL] [Abstract][Full Text] [Related]
9. Sildenafil Can Affect Innate and Adaptive Immune System in Both Experimental Animals and Patients.
Kniotek M; Boguska A
J Immunol Res; 2017; 2017():4541958. PubMed ID: 28316997
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy and tolerance of PDE-5 in the treatment of erectile dysfunction in schizophrenic patients: A literature review].
Bacconi L; Gressier F
Encephale; 2017 Feb; 43(1):55-61. PubMed ID: 27658991
[TBL] [Abstract][Full Text] [Related]
11. Comparisons of regular and on-demand regimen of PED5-Is in the treatment of ED after nerve-sparing radical prostatectomy for Prostate Cancer.
Qiu S; Tang Z; Deng L; Liu L; Han P; Yang L; Wei Q
Sci Rep; 2016 Sep; 6():32853. PubMed ID: 27611008
[TBL] [Abstract][Full Text] [Related]
12. PDE5A Polymorphisms Influence on Sildenafil Treatment Success.
Marchal-Escalona C; Herrera-Imbroda B; Clemente-Postigo M; Alcaide-Torres J; Quiñonero A; Marchal M; Queipo-Ortuño MI; Aragón IM; Martín-Morales A; Lara MF; Cardona F
J Sex Med; 2016 Jul; 13(7):1104-10. PubMed ID: 27235284
[TBL] [Abstract][Full Text] [Related]
13. Sildenafil Potentiates a cGMP-Dependent Pathway to Promote Melanoma Growth.
Dhayade S; Kaesler S; Sinnberg T; Dobrowinski H; Peters S; Naumann U; Liu H; Hunger RE; Thunemann M; Biedermann T; Schittek B; Simon HU; Feil S; Feil R
Cell Rep; 2016 Mar; 14(11):2599-610. PubMed ID: 26971999
[TBL] [Abstract][Full Text] [Related]
14. Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study.
Li WQ; Qureshi AA; Robinson KC; Han J
JAMA Intern Med; 2014 Jun; 174(6):964-70. PubMed ID: 24710960
[TBL] [Abstract][Full Text] [Related]
15. Intracavernosal OnabotulinumtoxinA Exerts a Synergistic Pro-Erectile Effect When Combined With Sildenafil in Spontaneously Hypertensive Rats.
Giuliano F; Joussain C; Denys P; Laurin M; Behr-Roussel D; Assaly R
J Sex Med; 2022 Jun; 19(6):899-906. PubMed ID: 35365400
[TBL] [Abstract][Full Text] [Related]
16. Exploring the Multifaceted Potential of Sildenafil in Medicine.
Pușcașu C; Zanfirescu A; Negreș S; Șeremet OC
Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138293
[TBL] [Abstract][Full Text] [Related]
17. PDE-5 inhibitors: clinical points.
Doumas M; Lazaridis A; Katsiki N; Athyros V
Curr Drug Targets; 2015; 16(5):420-6. PubMed ID: 25392015
[TBL] [Abstract][Full Text] [Related]
18. Natural phosphodiesterase 5 (PDE5) inhibitors: a computational approach.
Ongaro A; Zagotto G; Memo M; Gianoncelli A; Ribaudo G
Nat Prod Res; 2021 May; 35(10):1648-1653. PubMed ID: 31140295
[TBL] [Abstract][Full Text] [Related]
19. The two phases of the clinical validation of preclinical translational mechanistic research on PDE5 inhibitors since Viagra's advent. A personal perspective.
Gonzalez-Cadavid NF; Rajfer J
Int J Impot Res; 2019 Mar; 31(2):57-60. PubMed ID: 30258189
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
